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A B S T R A C T
Streptococcus pneumoniae capsular serotype 1 continues to pose a huge infectious disease burden in low- and
middle-income countries, particularly in West Africa. However, studies on this important serotype have been
hampered by the inability to genetically modify these strains. In this study we have genetically modified a
serotype 1 strain (519/43), the first time that this has been achieved for this serotype, providing the metho-
dology for a deeper understanding of its biology and pathogenicity. As proof of principle we constructed a
defined pneumolysin mutant and showed that it lost its ability to lyse red blood cells. We also showed that when
mice were infected intranasally with the mutant 519/43Δply there was no significant difference between the
load of bacteria in lungs and blood when compared to the wild type 519/43. When mice were infected in-
traperitoneally there were significantly fewer bacteria recovered from blood for the mutant 519/43Δply strain,
although all mice still displayed signs of disease. Our study demonstrates S. pneumoniae serotype 1 strains can be
genetically manipulated using our methodology and demonstrate that the ability to cause pneumonia in mice is
independent of active pneumolysin for the 519/43 serotype 1 strain.
1. Introduction
Streptococcus pneumoniae (S. pneumoniae, the pneumococcus) is a
major cause of morbidity and mortality worldwide. To date, nearly 100
serotypes of S. pneumoniae have been discovered [1–7]. Invasive
pneumococcal disease (IPD) is responsible for nearly 1 million deaths
per year in children under the age of 5 [8] with S. pneumoniae being the
leading cause of bacterial pneumonia, otitis media, meningitis and
septicaemia worldwide [9]. Over 90% of the pneumococcal burden is in
low income countries predominantly in sub-Saharan Africa, Latin
America and Asia [10–12]. Serotype 1 has been responsible for out-
breaks particularly in the African meningitis belt, where the highly
virulent sequence type ST217 is predominant [13–18]. Gessner et al.
showed that serotype 1 S. pneumoniae was as important as Neisseria
meningitidis for incidence and mortality of bacterial meningitis in the
African Meningitis Belt [19]. However, despite being found in invasive
disease often, this serotype is rarely found in carriage. For example, in
The Gambia, serotype 1 S. pneumoniae is responsible for about 20% of
all invasive disease cases and is only found in about 0.5% of healthy
carriers [17,20–22]. Serotype 1 has be shown to be carried for
approximately 9 days, being the second shortest carriage rate described
amongst pneumococci [23]. Competent pneumococci undergo genetic
exchange and recombination more efficiently in carriage rather than
invasive disease [24]. Since serotype 1 is rarely found in carriage the
hypothesis that it might have a lower recombination rate has been
proposed [25]. Recently, it has been reported that serotype 1 was dis-
seminated within the African continent but it diversified by country,
most likely due to population specific pressures, leading to stable cir-
culation of clones within its own geographic regions [26,27]. Sampane-
Donkor et al., reported that the current serotype 1 circulating sequence
types in West Africa are ST618, and ST612, ST3579, ST3960, ST3965
which are all variations of ST618. Most recently, Chaguza et al. have
added that the highly virulent sequence type ST217 has spread to dif-
ferent countries and continents [28]. To define why serotype 1 strains
are dominant causes of invasive disease in sub-Saharan Africa despite
their relative rarity in carriage a systematic analysis of mutated genes in
representative strains is required. However until now, all attempts of
mutagenesis in serotype 1 have been unsuccessful [29]. In this study we
report the mutagenesis of a serotype 1 strain, 519/43, that is capable of
acquiring and recombining new DNA into its genome. In order to
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T
demonstrate that mutations in this background are possible, a pneu-
molysin deficient mutant was constructed, verified and characterised
phenotypically in vitro and in vivo. Being able to investigate the effects
of mutating specific genes will allow a deeper understanding why ser-
otype 1 S. pneumoniae strains are dominant causes of meningitis in sub-
Saharan Africa.
2. Methods
2.1. Bacterial strains and growth conditions
Streptococcus pneumoniae serotype 2 strain D39 and serotype 1 strain
519/43 S T 5316 [30], isolated in 1943 in Denmark, acquired from the
Statens Serum Institute, were used in this study. Consistently, pneu-
mococci were grown in brain heart infusion (BHI) broth or on blood
agar plates supplemented with 5% (vol/vol) defibrinated horse blood
under microaerophilic conditions at 37 °C. Where appropriate, specti-
nomycin (100 μg/ml) was added to the culture medium.
Mutagenesis overview: The method used in this study starts by
using PCR-SOE to eliminate an important part of the gene of interest
and to introduce a restriction digestion site. In this case a 191 bp from
the middle of the ply gene was deleted and a BamHI site introduced.
This fragment was then cloned in pGEMTeasy using TA cloning to
generate pSD1 (Fig. 2). This plasmid was then digested at the newly
introduced BamHI site and ligated to a spectinomycin cassette termed
pSD2 (Fig. 4A). pSD2 was then used to transform 519/43WT, acting as
a suicide plasmid.
2.2. Splicing by overlapping extension PCR (SOE-PCR) [31] and
amplification of the spectinomycin cassette
PCR for the amplification of the upstream (488 bp) and downstream
(715 bp) homology arms from the flanking regions of the ply gene from
519/43 strain (serotype 1) was performed using plyFw1_ NotI,
plyRv1_BamHI, plyFw2_BamHI and plyRv2_NotI respectively (Table 1).
Primers used for the homologous arms for SOE_PCR were designed
using the D39 genome (NC_003098/NC_008533). The products were
analysed by gel electrophoresis and excised from the gel, followed by
purification according to the manufacturer's instructions (Monarch Gel
Extraction, NEB, UK). Next using equimolar amounts of upstream and
downstream homology arms as templates, these two fragments were
fused together by SOE PCR using primers plyFw1_ NotI, and plyRv2_-
NotI. At the time of the amplification relevant restriction sites were
introduced, BamHI at the SOEing site for later ligation of the specti-
nomycin cassette, as well as, NotI sites at the 5′ and 3′ of the PCR
product.
The spectinomycin cassette from plasmid pR412 (Dr Marc
PrudHomme CNRS-Universite Paul Sabatier Toulouse France) was
amplified using primers BamHI_SP2F2 and BamHI_SP2R2 (Table 1).
The PCR product was excised and purified as described above.
2.3. Construction of plasmid pSD1 and transformation of E. coli Dh5α
A ligation reaction was performed following the pGEMT-easy
system I manufacturer instructions (Promega, UK). Briefly, 5 μl 2X li-
gation buffer, 1 μl pGEMT-easy, 2 μl of the ply_SOE product, 1 μl T4
DNA ligase and water were combined in a microcentrifuge tube and
incubated overnight at 4 °C. This generated plasmid pSD1.
Chemically competent E. coli Dh5α (Invitrogen UK) were trans-
formed with pSD1. Briefly, 50 μl of E. coli Dh5α were incubated with
3 μl ligation reaction for 15 min on ice followed by thermic shock
(42 °C, 30 s). The cells were then placed on ice for 2 min. SOC media
was added and the cells recovered for 2 h at 37 °C. The transformation
was then plated on Luria Bertani Agar (LBA) and blue/white selection
used to discern the transformants carrying pSD1.
2.4. Extraction and restriction digestion of pSD1 and spectinomycin gene
and construction of pSD2
Plasmid DNA extraction was performed according to the manufac-
turer's instructions. (NEB, Monarch, UK). 1 μg of pSD1 and spectino-
mycin cassette were digested with BamHI at 37 °C for 3 h. The re-
striction digest was analysed by electrophoresis, excised and purified. A
ligation reaction was prepared using BamHI- digested pSD1 and spec-
tinomycin, following the pGEMT-easy system I manufacturer instruc-
tions (Promega, UK). Briefly, 5 μl 2X ligation buffer, 2 μl pSD1, 2 μl of
spectinomycin cassette, 1 μl T4 DNA ligase and water were combined in
a microcentrifuge tube and incubated overnight at 4 °C. This generated
plasmid pSD2. Plasmid pSD2 was transformed into E. coli Dh5α as de-
scribed above. Transformants carrying plasmid pSD2 were selected
based on their ability to grow in LBA supplemented with 100 μg/ml of
spectinomycin and ampicillin.
2.5. Transformation of S. pneumoniae strain 519/43
S. pneumoniae strain 519/43, ST 5316, serotype 1 was transformed
with 500 ng of pSD2. Briefly, S. pneumoniae 519/43 was grown over-
night in BHI at 37 °C, 5% CO2. In the morning the cultures were diluted
1:50 and 1:100 in 10 ml of fresh BHI broth (Oxoid, UK). The bacterial
suspension was incubated at 37 °C until the OD595nm was 0.05–0.1. At
this stage 860 μl were taken and put into a clear microcentrifuge tube
and 100 μl 100 mM NaOH, 10 μl 20% (w/v) BSA, 10 μl 100 mM CaCl2
and 2 μl 50 ng/ml CSP1 [32] were added. The reaction was then in-
cubated at 37 °C, statically for 3 h 330 μl were plated onto Blood Agar
Table 1
Primers used in this study for mutant construction, confirmation and sequencing. Primers used in the amplification of the homology arms and SOE_PCR
were designed using D39 genome as reference, primers designed later to sequence the mutants were designed using 519/43 genome data.
Primer name Sequence (5′-3′) Gene






BamHI_SP2F2 GGATCC CTA GAA CTA GTG GAT CCC CC spc cassette from pR412
BamHI_SP2R2 GGATCC AAT TCT GCA GAT TTT AC ATG ATC spc cassette from pR412
SPEC_REV TAATTCCTCTAAGTCATAATTTCCG spc cassette from pR412
plySCN1 CCAATGGAAATCGCTAGGCAAGAGATAA +/1602753
plySCN2 ATTACTTAGTCCAACCACGGCTGAT SWT_01592
spec_sqr1 CCTGATCCAAACATGTAAGTACC spc cassette from pR412
spec_sqf2 CGTAGTTATCTTGGAGAGAATA spc cassette from pR412
spec_sqf1 GGTACTTACATGTTTGGATCAGG spc cassette from pR412
spec_sqr2 TATTCTCTCCAAGATAACTACG spc cassette from pR412
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(BA) plates supplemented with 100 μg/ml spectinomycin, every hour
over the 3 incubation hours. The plates were incubated overnight at
37 °C, 5% CO2. Spectinomycin resistant colonies were patched onto
another BA plate supplemented with 100 μg/ml spectinomycin. They
were also plated in BA supplemented with 100 μg/ml ampicillin to test
for the presence of the plasmid backbone. Presence of the spectino-
mycin cassette was determined by PCR using primers plyFw1_ NOTI
and SPEC_REV and confirmation of the mutation was performed using
primers plySCN1 and plySCN2 (Table 1).
2.6. Phenotypic characterisation
2.6.1. Assessment of 519/43Δply ability to grow in BHI
Growth impairment was assessed by growth curves. 100 μl of iso-
genic mutant 519/43Δply and wild type 519/43 were inoculated into
10 ml BHI broth (Oxoid, UK). The cultures were grown at 37 °C stati-
cally, in an incubator with 5% CO2 for 24 h. Optical density (OD) was
read at 600 nm every 2 h from time 0 h to time 8 h, and then one last
measurement was taken at 24 h.
2.6.2. Assessment of 519/43Δply ability to grow in serum
Wild-type and ply-deleted S. pneumoniae (519/43) were grown in
Todd-Hewitt broth supplemented with 0.5% yeast extract (THY) to mid-
log phase at 37 °C in 5% CO2. Bacterial density was calculated by
counting the colony forming units (CFU) in 100 μl of ten-fold serially
diluted stocks on Colombia agar supplemented with horse blood after
24 h. Stocks of each isolate were made in 80% glycerol and stored at
−80 °C. Stocks were thawed, washed and re-suspended at a starting
bacterial count of 1 × 105 CFU in healthy donor human serum. Each
sample was cultured in triplicate in 100 μl volume at 37 °C in 5% CO2
for 24 h in the Tecan Spark® microplate reader (Tecan, USA). Optical
density (OD) readings at 600 nm were taken every 30 min. Data were
plotted using Prism version 7.
2.6.3. Expression of Pneumolysin in 519/43 WT and 519/43Δply
Expression of Pneumolysin was assessed by Western blot. Briefly,
bacterial cultures were grown overnight at 37 °C, statically. The next
day, 1 ml of culture was taken spun down at 5000×g. The pellet was
resuspended in 50 μl of NuPage LDS Sample buffer (4X) (Thermo Fisher
Scientific, UK) and the samples boiled for 10 min 50 μl of supernatant
were also taken from the overnight grown cultures. 10 μl of the cell
lysates and supernatants of both 519/43 WT and 519/43Δply were run
in a NU-PAGE 4–12% Bis-Tris Protein Gel (Thermo Fisher Scientific,
UK) and blotted onto a PVDF membrane using a iBlot 2 (Thermo Fisher
Scientific, UK). The presence of Pneumolysin was assessed using Mouse
Anti-Pneumolysin antibody [PLY-4] (abcam, UK) and detected using
IRDye®680RD Goat anti-mouse IgG (H + L).
2.6.4. Haemolysis assessment
Supernatant of pneumococcal bacterial cultures from 519/43, 519/
43Δply and D39 were mixed with a 5% solution of horse blood in
Alseevers (RBCs) in PBS and incubated in triplicate at 37 °C for 30 min
in 96-well round-bottom plates. The plates were centrifuged at 2300×g
for 5 min to pellet non lysed RBCs. The supernatants were carefully
transferred to another 96-well round bottom plate and the supernatants
were measured for haemoglobin content by spectrophotometry at
A450. Saponin 0.5% was used as the positive control representing
100% haemolysis. Haemolysis percentages were determined by aver-
aging the absorbance values for each sample and converting them to a
percent value when compared to the positive control (Saponin 0.5%).
2.6.5. In vivo virulence of 519/43 Δply
Mice (5-6-week-old CD1, Charles River) were anaesthetised with
isoflurane then given 50 μl of bacteria suspended in PBS intranasally by
pipetting onto the nares (Dose 519/43: 3.4 × 107, 519/43Δply:
5.0 × 107). Alternatively, mice were injected with 100 μl of bacterial
suspension intraperitoneally (dose 519/43: 3.45 × 104; 519/43Δply:
3.8 × 104) without anaesthesia. The challenge dose was confirmed by
retrospectively diluting and plating the culture on blood agar. Mice
were euthanized at the pre-determined time points (24h post infection)
by CO2 asphyxiation. Blood was collected from the aorta. Following
perfusion with PBS, the lungs were excised. These samples were
homogenised in 1 ml PBS using a Precellys® 24 tissue homogeniser
[Bertin Technologies, France]. Samples of the blood and lungs were
then serially diluted in serum broth and colonies were enumerated after
overnight growth on blood agar plates supplemented with spectino-
mycin when appropriate.
3. Results
3.1. Generation of plasmid pSD1
A pneumolysin mutant was made in the 519/43 serotype 1 S.
pneumoniae strain as described in the Material and Methods section.
Firstly, upstream and downstream homology arms were amplified using
DNA from both D39 (serotype 2) and 519/43 (serotype 1) Fig. 1, lanes 2
and 3, 4 and 5 respectively. At the time that this mutant was con-
structed strain 519/43 was not sequenced. Therefore, to ensure the
primers were functional, D39 genomic DNA was used as a positive
control for the binding. Secondly, SOE-PCR was performed to fuse the
right and left DNA arms as a 1235 bp product (Fig. 1, lanes 6 and 7)
whilst introducing a BamHI site at the junction of upstream and
downstream DNA arms. The 1235bp product was TA-cloned into
pGEM-Teasy. This generated plasmid pSD1.
3.2. Generation of plasmid pSD2
Plasmid pSD2 containing a suitable antibiotic resistance cassette
between the 5′ and 3’ arms of the sequences flanking ply was created by
BamHI digestion of plasmid pSD1 (Fig. 3, lane 1) and ligation to a
previously digested spectinomycin cassette (Fig. 3, lane 4) as described
above. The insertion of the spectinomycin cassette was at the junction
of the upstream and downstream homology arms where the BamHI site
was introduced at the time of the PCR. Strain 519/43 was then trans-
formed with 500 ng of plasmid pSD2 using CSP1 to induce competence.
The transformation yielded 10 colonies. 7 out of the 10 were positive
for the spectinomycin insertion confirmed by PCR.
The mutation by insertion of the spectinomycin cassette on 519/43
Fig. 1. Amplification of homology arms (left hand side of the figure); and
Splicing by Overlapping Extension PCR (right hand side of the figure). L-ladder,
lane 1- negative control for the reaction, lane 2 and 3- left (527 bp) and right
(756 bp) homology arm amplified from D39 gDNA, lanes 4 and 5- left (527 bp)
and right (756 bp) homology arms amplified from 519/43 gDNA. Right hand
side lane 6- D39 SOE PCR product, lane 7–519/43 SOE PCR product (1235 bp).
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genome was confirmed in two transformants by sequencing with pri-
mers spec_sqr1, spec_sqf2, spec_sqf1 and spec_sqr2, plySCN1 and plySCN2
(Table 1) (Fig. 4B). Primers plySCN1 and plySCN2 (Table 1) were de-
signed with attachment site outside of the homology zone to confirm
the insertion of the spectinomycin cassette in the chromosome.
3.3. Growth of the Δply mutants in rich media and in healthy donor serum
Mutations by insertion can on occasion cause growth defects. To
ascertain that this was not the case isogenic Δply mutants and wild type
strain were cultured in BHI (rich media) and growth monitored using
optical density. There were no significant differences in growth be-
tween the isogenic mutant 519/43Δply and the wild type 519/43
strains, demonstrating that the insertion did not cause any noticeable
growth defect in rich media (Fig. 5A). On the other hand, there were
significant differences when 519/43WT and 519/43Δply were grown in
serum. Where the wild type strain was able to continue growing ex-
ponentially the same wasn't observed for the mutant. The mutant grew
at similar rate until 7 h when the growth defect became noticeable.
From then until the end of the experiment (24 h) 519/43Δply continued
to grow but at a much lower rate when compared with the wild type
(p < 0.05) (Fig. 5B).
3.4. Expression of Pneumolysin in 519/43 WT and 519/43Δply
The expression of Pneumolysin was assessed by western blot to
confirm that the protein was no longer present as it could still have a
cytotoxic effect. It was clear that Pneumolysin was not present on 519/
43Δply in either the cell lysate or in the supernatant but it was present
in the wild type (Fig. 6A).
3.5. Haemolysis assessment
Pneumolysin is responsible for red blood cell lysis by S. pneumoniae.
Hence, a haemolysis assay was used to confirm that the mutation had
rendered pneumolysin non-functional. Saponin was used as the positive
control (100% haemolysis after 30 min incubation), and percentage
values for all samples were calculated against saponin. In comparison to
saponin, 519/43WT lysed 67.3% red blood cells (RBCs) in a 30 min
incubation period; by contrast the defined 519/43Δply mutant lysed
only 2.5% of the cells (Fig. 6B). As the pneumolysin allele present in
519/43WT is different to the D39 allele (it contains one amino acid
substitution, D380 N) the haemolysis of the D39 strains were also as-
sessed. This one amino acid substitution is often observed on ST227
strains [33] and does not seem to confer a haemolytic advantage. D39
pneumolysin had an activity of 56.8% when compared to saponin
control, a lower activity than that recorded for 519/43 WT although the
difference was not statistically significant. The data confirm that the
insertion of the spectinomycin cassette has disrupted the ability of
pneumolysin to lyse RBCs.
Fig. 2. A Scheme depicting the strategy used for SOE-PCR (A). B- Depicting how pSD1 was generated. C- Mapping of the homology arms to the pneumolysin gene.
Fig. 3. Confirmation of presence of spectinomycin cassette in pSD2. L-hy-
perladder 1 kb (Bioline); 1- pSD1 digested with BamHI; 2-pSD2 digested with
BamHI; L hyperladder 1 kb; 3- Spectinomycin cassette amplified from pR412, 4-
Spectinomycin cassette digested with BamHI.
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3.6. Role of 519/43 pneumolysin in infection
Due to the known multiple roles of pneumolysin on virulence and
since some serotype 1 strains (ST306) express a non-haemolytic pneu-
molysin [34], the contribution of this protein to infection in strain 519/
43 was assessed. Outbred CD1 mice were infected intraperitoneally
with 519/43 (3.5 × 104 cfu/ml) and 519/43Δply (3.8 × 104 cfu/ml).
The data showed that after 24 h there was a statistically significant
difference in the number of pneumococci present in blood with
2.9 × 107 cfu/ml of the 519/43 strain and 6.2 × 105 cfu/ml of the
519/43Δply strain (p < 0.01, n = 10), suggesting a role for pneu-
molysin during systemic infection (Fig. 7).
However, the same trend wasn't observed for the pneumonia
models. When mice were infected with 519/43 (3.4 × 107 cfu/ml) and
519/43Δply (5.0 × 107 cfu/ml) intranasally there were no significant
differences between cfu present in blood (519/43WT: 5.4 × 104 cfu/ml
and 519/43Δply: 7.6 × 104 cfu/ml) or in the lungs (519/43:
3.8 × 104 cfu/ml) and 519/43Δply: 4.9 × 104 cfu/ml) between the
wild type and the isogenic mutant after 24h of infection (Fig. 8).
4. Discussion
Streptococcus pneumoniae, particularly serotype 1, continues to pose
a threat in most low- and middle-income countries. Despite the
Fig. 4. (A) Scheme showing the assembly of plasmid pSD2. (B) Mapping of the sequencing data to the chromosomally inserted ply_spec
Fig. 5. (A) Growth of 519/43WT and 519/43Δply in BHI (Oxoid, UK) over 24h. ● represents 519/43WT and ▪ represents 519/43 Δply. For each time point there are
three technical and two biological replicates (B) Growth of 519/43WT and 519/43Δply in healthy donor serum over 24 h ● represents 519/43WT and ▪ represents
519/43 Δply. For each time point there are three technical repeats.
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introduction of the vaccines PCV7, PCV10 and more recently PCV13
that include polysaccharide in their formulation to protect against
serotype 1, this important serotype is still capable of causing outbreaks
that lead to high mortality and morbidity. Because of its clinical im-
portance, the ability to genetically manipulate serotype 1 isolates is
paramount but has not, to our knowledge, previously been described.
In this study we report a serotype 1 strain 519/43 (ST5316), a
clinical isolate from a meningitis patient in Denmark, that we have
genetically manipulated to the same extent as other serotypes e.g.
strains D39 (serotype 2) or TIGR4 (serotype 4). The success of our en-
deavour relies entirely on the choice of strain and on the transformation
of 519/43 with a plasmid instead of linear DNA (the conventional
methodology in S. pneumoniae mutagenesis); All attempts using linear
DNA were unsuccessful. The reason why this strain can be genetically
modified and other serotype 1 strains cannot, remain unknown.
Genome sequences suggest that all natural competence genes in 519/43
are intact, whereas this is not true for all sequenced serotype 1 strains in
which, for example, comD can be truncated or comE absent [35]. De-
spite this strain not being an important African sequence type, it was
isolated from a meningitis patient making it a good candidate strain to
study and understand the development of pneumococcal meningitis.
In order to show that this strain can be mutated, an insertion mu-
tation was made in the pneumolysin gene. This gene was targeted as it
has a readily identifiable phenotype in vitro, but we have also used the
same approach to make mutations affecting additional genes in the
serotype 1 strain 519/43 (ST5316) (manuscript in preparation).
We demonstrated that strain 519/43 has a haemolytic pneumolysin
and that its function can be interrupted by inserting an antibiotic
Fig. 6. A- Expression of Pneumolysin in 519/
43WT and isogenic mutant 519/43Δply. L-
PageRuler Plus prestained protein ladder, 1-
Pneumolysin present in cell lysate of 519/43WT,
2- Absence of Pneumolysin in 519/43Δply cell ly-
sate; 3- Presence of Pneumolysin in 519/43WT
supernatant; 4- Absence of Pneumolysin in 519/
43Δply supernatant. B- Determination of haemo-
lytic activity of D39, 519/43WT and isogenic
mutant 519/43Δply, when compared to 0.5% sa-
ponin. Saponin-derived haemolysis is considered
100% and the values for 519/43 wt and 519/
43Δply were calculated against this. Each value
plotted is the mean of 5 technical and 3 biological
replicates.
Fig. 7. Intraperitoneal infection of CD1 mice. Each dot represents 1 mouse.
Presented is the geometric mean with 95% CI. Mice were euthanized humanely
at 24 h post infection and the cfu in blood enumerated.
Fig. 8. Intranasal infection of CD1 mice. Each dot represents 1 mouse. (A) Cfu/ml present in blood after intranasal infection. (B) cfu/ml present in the lungs after
intranasal infection. Presented is the geometric mean with 95% CI. Mice were euthanized humanely at 24h post infection and the cfu in blood and lungs enumerated.
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marker in its place. We also observed that the one amino acid sub-
stitution (D380N) common to our strain and to strains from ST227 [34]
does not confer a higher ability to lyse RBCs in vitro. We also showed
that pneumolysin mutation does not seem to impact bacterial growth in
complete laboratory media, whereas this mutant had impaired growth
in serum compared to the wild type strain. We showed that the hae-
molytic pneumolysin carried by 519/43 has an apparent role in in-
vasive disease as we found significantly fewer bacteria in the blood of
mice when challenged intraperitoneally with the loss of function mu-
tant 519/43Δply. Nevertheless, although there were significantly fewer
bacteria in blood at 24 h post infection, invasive disease still occurred
and consequently the mice displayed visible signs of disease. A similar
phenotype was observed for the pneumolysin deficient mutant of D39
[29,36]. In the past it was thought that pneumolysin was essential for
IPD, but our data suggests that this is not the case for serotype 1 S.
pneumoniae. Further support for this is provided by previous publica-
tions; Kirkham et al., demonstrated that a strain carrying a naturally
occurring non-haemolytic pneumolysin did not prevent ST306 strains
from causing invasive disease when infected intraperitoneally with
ST306 or ST227 presenting with bacteraemia within 24 h of infection.
Additionally Jefferies et al. reported that a clinical strain S1-11 (ST228)
that is unable to express pneumolysin allele 14 due to the insertion of a
mobile element within its gene was isolated from the blood of a patient
with pneumonia, suggesting this strain could still cause disease and
progress from the lungs to the blood [33].
In our study we observed that when mice were infected intranasally,
there was no significant differences in bacterial load in blood and lungs
between the 519/43 wild type and Δply strains. Similar results were
observed by Kirkham et al. when they compared intranasal challenge
by 01–2696 (ST227) that possesses a haemolytic pneumolysin with
01–1956 (ST306) that has a non-haemolytic pneumolysin; they ob-
served no difference in bacterial loads and all mice were bacteraemic
after 24 h. Conversely, Paton et al., showed that a sequence type as-
sociated with an outbreak carried a reduced haemolytic activity ply
allele, and that mice infected with D39 carrying this reduced haemo-
lysis allele for pneumolysin survived about 4 h longer than mice in-
fected with D39. This was clearly different for mice infected with
D39Δply, who survived 8 h longer than their wild type counterpart.
Importantly, the studies described by Paton et al. were done by trans-
ferring the pneumolysin from serotype 1 into D39 due to difficulties
with mutagenesis in the serotype 1 strain. This could have had a sig-
nificant impact on the observations reported and highlights the im-
portance of making mutations in the correct strain background as in our
study. Nevertheless, there seems to be a high degree of variation on the
role and contribution of pneumolysin for IPD depending on serotype,
and perhaps even sequence type [29]. In our study we were unable to
discern which animals survived the longest as the experiment had a pre-
defined ending time point. These data suggest that, as other reports for
serotype 1 strains [34], strain 519/43 is not dependent on haemolytic
pneumolysin to cause disease. Further experiments are necessary to
thoroughly understand the role of serotype 1 pneumolysin in invasive
disease.
Research is undergoing to expand which serotype 1 strains can be
transformed and therefore allowing the construction of targeted mu-
tations in genes of interest. Finally, the focus of this study was to pro-
vide the scientific community with a serotype 1 strain that can be ge-
netically manipulated allowing many questions to be answered
especially elucidating the role of determinants involved directly in
survival, colonisation and disease, particularly in relation to meningitis.
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